...and it appears that they did get something from the discontinued stuff (FWIW), and possibly (?) avoided paying for some redundacies -
ALAMEDA, Calif., Oct. 29 /PRNewswire/ -- Xenogen Corporation today announced that it has completed a licensing and asset acquisition from Incyte Genomics. This cash based acquisition includes a lab and animal facility based in St. Louis, MO, accompanying significant leasehold and other fixed assets, and a non-exclusive license to a package of intellectual property that we believe will benefit Xenogen's overall commercial endeavors. In addition, a number of highly-trained and skilled scientists and technicians have agreed to join Xenogen's newly commenced operations in St. Louis, bringing their expertise in the development and commercial manufacture of animal models used in drug discovery and development programs.
As a result of this transaction, Xenogen Corporation now has three strategic locations -- Alameda, CA, Cranbury, NJ and St. Louis, MO. The company, employing approximately 190 employees, offers a range of high-class research and development and products and services from these key locations that are used by numerous pharmaceutical and biotech customers.
``This acquisition expands Xenogen's capacity to produce high quality animal models on a commercial basis,'' stated Pamela Reilly Contag, Ph.D., President and co-CEO of Xenogen Corporation. ``These new capabilities will allow Xenogen to consolidate its ability and expertise to offer our customers the animal models based on specific genes and pathways that can be used in generating valuable and relevant data for their commercial drug discovery and development programs.''
About Xenogen Corporation
Xenogen Corporation is a leader in the field of real-time in vivo imaging, providing the pharmaceutical industry with proprietary technologies, products and services to enable real-time in vivo monitoring to identify drug leads for clinical development. In addition to pharmaceutical development, Xenogen believes that its technology has broad applications in other fields, including biomedical research and toxicology testing in the chemical industry.
For more information, visit the Xenogen web site at www.xenogen.com.
ALAMEDA, Calif., Oct. 29 /PRNewswire/ -- Xenogen Corporation today announced that it has completed a licensing and asset acquisition from Incyte Genomics. This cash based acquisition includes a lab and animal facility based in St. Louis, MO, accompanying significant leasehold and other fixed assets, and a non-exclusive license to a package of intellectual property that we believe will benefit Xenogen's overall commercial endeavors. In addition, a number of highly-trained and skilled scientists and technicians have agreed to join Xenogen's newly commenced operations in St. Louis, bringing their expertise in the development and commercial manufacture of animal models used in drug discovery and development programs.
As a result of this transaction, Xenogen Corporation now has three strategic locations -- Alameda, CA, Cranbury, NJ and St. Louis, MO. The company, employing approximately 190 employees, offers a range of high-class research and development and products and services from these key locations that are used by numerous pharmaceutical and biotech customers.
``This acquisition expands Xenogen's capacity to produce high quality animal models on a commercial basis,'' stated Pamela Reilly Contag, Ph.D., President and co-CEO of Xenogen Corporation. ``These new capabilities will allow Xenogen to consolidate its ability and expertise to offer our customers the animal models based on specific genes and pathways that can be used in generating valuable and relevant data for their commercial drug discovery and development programs.''
About Xenogen Corporation
Xenogen Corporation is a leader in the field of real-time in vivo imaging, providing the pharmaceutical industry with proprietary technologies, products and services to enable real-time in vivo monitoring to identify drug leads for clinical development. In addition to pharmaceutical development, Xenogen believes that its technology has broad applications in other fields, including biomedical research and toxicology testing in the chemical industry.
For more information, visit the Xenogen web site at www.xenogen.com. |
